Gastrointestinal Medicines · LP-083
Omeprazole Capsules
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-083Gastrointestinal Medicines
- Generic identity
- OmeprazoleCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-083
- Generic identity
- Omeprazole
- Presentation
- Capsule
- Catalogue strength
- 10 mg; 20 mg; 40 mg
- Catalogue pack
- Blister 10 x 10 capsules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Omeprazole.
- Dosage form: Capsule.
- Catalogue strength / concentration: 10 mg; 20 mg; 40 mg.
- Catalogue pack: Blister 10 x 10 capsules.
- Catalogue category: Gastrointestinal Medicines; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Release/enteric-protection design, pellet/granule composition and capsule-opening/alteration instructions.
- Controlled SKU mapping for the three strengths.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
Current external omeprazole labels commonly identify delayed-release capsules. That demonstrates why release character is material but does not establish LP-083 formulation.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg | Capsule | — | Catalogue lists blister 10 x 10 capsules; strength-specific controlled SKU evidence not supplied | Do not infer delayed-release/gastro-resistant technology, opening instructions or interchangeability. |
| B | 20 mg | Capsule | — | Catalogue lists blister 10 x 10 capsules; strength-specific controlled SKU evidence not supplied | Do not infer delayed-release/gastro-resistant technology, opening instructions or interchangeability. |
| C | 40 mg | Capsule | — | Catalogue lists blister 10 x 10 capsules; strength-specific controlled SKU evidence not supplied | Do not infer delayed-release/gastro-resistant technology, opening instructions or interchangeability. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Omeprazole is a proton-pump inhibitor that reduces gastric acid secretion. It is used in selected reflux, ulcer and other acid-related conditions, sometimes within a clinician-directed combination. Different capsule and granule products have formulation-specific instructions. This educational ingredient profile does not establish Luang Pharma approved labeling, a confirmed enteric-coating design or a reason to continue acid suppression without periodic clinical review.
Clinical context and therapeutic role
Assessment should identify the symptom pattern and any features requiring investigation, such as bleeding, progressive swallowing difficulty, unexplained weight loss or persistent vomiting. A clinician determines whether a proton-pump inhibitor is appropriate and whether testing or other treatment is needed. Medication review matters, particularly with clopidogrel and medicines affected by gastric pH. Continued therapy should have a clear indication; relief of heartburn does not exclude another underlying condition.
Selected safety context
Headache, abdominal discomfort, diarrhoea or constipation may occur. Kidney inflammation, low magnesium and vitamin B12 deficiency are important considerations in relevant settings, particularly prolonged treatment. Some gastrointestinal infections and fracture risks are associated with long-term use and need clinical context. Severe diarrhoea, reduced urine, marked weakness or allergic symptoms warrants assessment. Altering gastro-resistant granules can affect performance, so opening or crushing a capsule requires confirmation from the exact product information.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes an oral capsule. Capsule shell, fill composition and release behavior are product-specific and are not established by the ingredient name. Opening a capsule or dispersing its contents should be considered only when the approved instructions or a pharmacist confirms that this is appropriate.
Retain the original labeled pack and check its integrity and expiry before use. Storage requirements must come from the supplied product information; no shelf life or temperature is inferred here. A pharmacist can advise on an alternative presentation if swallowing is difficult.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: OmeprazoleArchived source classification: public-health medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Omeprazole delayed-release capsules — external label exampleArchived source classification: US official drug label example | Source revision recorded: Updated 30 June 2026; Archived access check: 2026-09-11 | External comparator explicitly identifying delayed-release formulation; not evidence of LP-083 release design or equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-083.
Professional enquiries
Request product-specific evidence for LP-083.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.